CATT: Ranibizumab and Bevacizumab Had Similar Effects on Visual Acuity Over 2 Years
Second-year results from the pivotal Comparison of
Age-Related Macular Degeneration Treatment Trials
(CATT) comparing bevacizumab (Avastin, Genentech)
and ranibizumab (Lucentis, Genentech) found that the
drugs are equivalent in treating neovascular age-related
macular degeneration (AMD) when administered using
similar...